Komori
Earnings presentation3407ASAHI KASEI CORPORATIONMaterials and Chemicals

Financial Results Presentation for the First Quarter of Fiscal 2026

In the first quarter of FY2026, revenue was ¥826.2 billion and operating income was ¥81.3 billion, representing year-on-year increases in both revenue and operating income. Expanded sales of pharmaceuticals, critical care and electronics, inventory valuation effects in Materials, and the weaker yen contributed to higher profits.

Worth reading
78Important
Scored from 5 of 6 sections
Direction
Improvement
Direction inferred from the company’s description.
Scale
277
¥100 million (year-on-year increase in operating profit)
Wording
Conditional
How definitive the wording is.

Contents of this document

Earnings presentationFY2026 First Quarter12 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥8,262 100 million+11.9%
Operating profit¥813 100 million+51.5%
Net income¥538 100 million+172.7%
Operating profit margin9.8 %
Results for the three months of the current quarter
Net Sales
¥8,262 100 million
Operating profit
¥813 100 million
Profit attributable to owners of parent for the quarter
¥538 100 million
What the company explained in this material
Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.
Consolidated operating profit
Foreign exchange110
Key market-related impacts on Materials110
Business transfers and new consolidations-25
Revenue and profitability improvements centered on priority growth businesses81
Healthcare
Volume factors86
Selling-price factors15
Foreign exchange3
Other factors-33
Housing
Revenue factors4
Contribution-margin factors0
Fixed-cost factors3
Overseas business factors-28
Other factors0
Materials
Volume factors46
Selling-price factors272
Raw materials and fuel factors-304
Foreign exchange81
Other factors144
Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.
Average exchange rate (U.S. dollar)¥160 (Q1 actual), ¥155 (Q2 forecast)
Average exchange rate (euro)¥185 (Q1 actual), ¥180 (Q2 forecast)
Domestic naphtha price¥118,900/kl (Q1 actual), ¥95,000/kl (Q2 forecast)
New initiatives
  • Acquisition and new consolidation of Aicuris
  • Capacity expansion investment for Paimel (¥16.0 billion; production launch in the first half of FY2028)
  • Expansion of production capacity for alkaline water electrolysis systems for clean hydrogen production (¥31.0 billion; production launch in FY2028)
  • Construction of a new Planova spinning plant (¥23.4 billion; commercial production launch in the second half of FY2029)
  • Introduction of a special incentive program for the employee shareholding association
Key KPIsA metric the company considers important as a management benchmark.
  • EBITDA¥1,339 100 million+32.6%
  • Revenue EBITDA margin16.2 %
    yoy_change_points2.5
  • Envarsus XR U.S. revenue99 USD million+16.5%
  • Tarpeyo U.S. revenue95 USD million+12.4%
  • ACT revenue373 USD million+10.0%
  • CMS revenue274 USD million+11.4%
  • Construction contracting orders
  • D/E ratio0.62 times
Unit price and quantity metricsThese figures show sales broken down by price and volume.
The materials discuss higher average unit prices in the construction contracting business and increases in sales volumes and quantities for pharmaceuticals, critical care and electronics, among others. A combined numerical disclosure covering all volume and unit-price indicators was not disclosed.
Segment results
Healthcare
Net Sales
¥1,908 100 million
Revenue YoY (%)23
Operating profit
¥298 100 million
Operating Profit YoY (%)31.4
Housing
Net Sales
¥2,676 100 million
Revenue YoY (%)3.3
Operating profit
¥202 100 million
Operating Profit YoY (%)-9.7
Materials
Net Sales
¥3,602 100 million
Revenue YoY (%)13.8
Operating profit
¥388 100 million
Operating Profit YoY (%)160.4
Medium-term management plan targets
Operating profit
¥2,700 100 million
Target fiscal yearFY2027
FY2030 operating income outlook
¥3,800 100 million
Target fiscal yearFY2030
Financial targets
Indicative D/E ratio level0.7 times
Actual results0.62 times
Orders received and order backlog
Construction contracting orders
FY2026 first-half forecast
¥2,215 100 million+10.3%
Annual Dividend
Annual Dividend
¥44 per share
Interim Dividend
¥22 per share
Payout ratio
36.8 %
DOE guideline3%
Acquisition of treasury shares
Maximum amount
¥400 100 million
Period6 November 2025 to 31 October 2026
Contents of this document
ItemDetails
Document typeEarnings presentation
Fiscal Period CoveredFY2026 First Quarter
Net Sales¥8,262 100 million (YoY +11.9%)
Operating profit¥813 100 million (YoY +51.5%)
Net income¥538 100 million (YoY +172.7%)
Operating profit margin9.8 %
Results for the three months of the current quarterNet Sales ¥8,262 100 million / Operating profit ¥813 100 million / Profit attributable to owners of parent for the quarter ¥538 100 million
Segment resultsHealthcare Net Sales ¥1,908 100 million / Revenue YoY (%) 23 / Operating profit ¥298 100 million / Operating Profit YoY (%) 31.4 / Housing Net Sales ¥2,676 100 million / Revenue YoY (%) 3.3 / Operating profit ¥202 100 million / Operating Profit YoY (%) -9.7 / Materials Net Sales ¥3,602 100 million / Revenue YoY (%) 13.8 / Operating profit ¥388 100 million / Operating Profit YoY (%) 160.4
Breakdown of Factors Affecting the ChangeConsolidated operating profit Foreign exchange 110 / Key market-related impacts on Materials 110 / Business transfers and new consolidations -25 / Revenue and profitability improvements centered on priority growth businesses 81 / Healthcare Volume factors 86 / Selling-price factors 15 / Foreign exchange 3 / Other factors -33 / Housing Revenue factors 4 / Contribution-margin factors 0 / Fixed-cost factors 3 / Overseas business factors -28 / Other factors 0 / Materials Volume factors 46 / Selling-price factors 272 / Raw materials and fuel factors -304 / Foreign exchange 81 / Other factors 144
Key KPIsEBITDA ¥1,339 100 million (YoY +32.6%), Revenue EBITDA margin 16.2 %, Envarsus XR U.S. revenue 99 USD million (YoY +16.5%), Tarpeyo U.S. revenue 95 USD million (YoY +12.4%), ACT revenue 373 USD million (YoY +10.0%), CMS revenue 274 USD million (YoY +11.4%), Indicator name Construction contracting orders / value Not disclosed / yoy_pct Not disclosed, D/E ratio 0.62 times
Unit price and quantity metricsThe materials discuss higher average unit prices in the construction contracting business and increases in sales volumes and quantities for pharmaceuticals, critical care and electronics, among others. A combined numerical disclosure covering all volume and unit-price indicators was not disclosed.
Assumptions Underlying the Business OutlookAverage exchange rate (U.S. dollar) ¥160 (Q1 actual), ¥155 (Q2 forecast) / Average exchange rate (euro) ¥185 (Q1 actual), ¥180 (Q2 forecast) / Domestic naphtha price ¥118,900/kl (Q1 actual), ¥95,000/kl (Q2 forecast)
Medium-term management plan targetsOperating profit ¥2,700 100 million / FY2030 operating income outlook ¥3,800 100 million
Financial targetsIndicative D/E ratio level 0.7 times / Actual results 0.62 times
Annual DividendAnnual Dividend ¥44 per share / Interim Dividend ¥22 per share / Year-end dividend Not disclosed
Payout ratio36.8 %
Acquisition of treasury sharesMaximum amount ¥400 100 million / Period 6 November 2025 to 31 October 2026
Orders received and order backlogConstruction contracting orders FY2026 first-half forecast ¥2,215 100 million (YoY +10.3%)
New initiativesAcquisition and new consolidation of Aicuris, Capacity expansion investment for Paimel (¥16.0 billion; production launch in the first half of FY2028), Expansion of production capacity for alkaline water electrolysis systems for clean hydrogen production (¥31.0 billion; production launch in FY2028), Construction of a new Planova spinning plant (¥23.4 billion; commercial production launch in the second half of FY2029), Introduction of a special incentive program for the employee shareholding association
Items this document does not state (12)
Ordinary incomeGross Profit MarginSelling, general and administrative expensesFull-year earnings forecastProgress against full-year forecastSelf-assessment against the planNumber of stores and locationsNumber of employeesRisk amount incorporated into the outlookCapital expendituresMarket Size / ShareKey points of the Q&A

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

Expanded sales of core products in the Pharmaceuticals, Critical Care and Electronics businesses, which are designated as "priority growth" businesses, the impact of the weaker yen, and positive inventory valuation effects in Materials, including essential chemicals.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.
Financial Results Presentation for the First Quarter of Fiscal 2026 | ASAHI KASEI CORPORATION (3407) timely disclosure | Komori